FIGURE 8.

A schematic model for ITGB8‐mediated lenvatinib resistance in HCC. Lenvatinib treatment kills HCC cells and suppresses HCC development. However, HCC cells acquire resistance to lenvatinib treatment by increasing the expression of ITGB8. ITGB8 increases the expression of HSP90, which stabilizes AKT expression and enhances AKT activity, thus leading to lenvatinib resistance. In support of this model, functional inhibition of ITGB8 by shRNA, AKT inhibitor MK‐2206, or HSP90 inhibitor 17‐AAG resensitizes LR HCC cells to lenvatinib treatment. TMA, tissue microarray